<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02506179</url>
  </required_header>
  <id_info>
    <org_study_id>P15-325</org_study_id>
    <nct_id>NCT02506179</nct_id>
  </id_info>
  <brief_title>Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis</brief_title>
  <acronym>UCanADA</acronym>
  <official_title>A Study of the Impact of Adalimumab on Patient-reported Outcomes (PROs) in Canadian Patients Suffering From Moderate-to-severe Ulcerative Colitis (UCanADA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cato Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the real-life effect after 1 year of adalimumab treatment on psychological
      distress/depression symptoms in moderate-to-severe Ulcerative Colitis (UC) patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 18, 2015</start_date>
  <completion_date type="Actual">February 10, 2020</completion_date>
  <primary_completion_date type="Actual">February 10, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in depressive symptoms at Week 52</measure>
    <time_frame>From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>It is measured by the Patient Health Questionnaire - 9 Items (PHQ-9).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in depressive symptoms at Week 8</measure>
    <time_frame>From Week 0 to Week 8, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>It is measured by the Patient Health Questionnaire - 9 Items (PHQ-9).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the proportion of patients with PHQ-9 &gt;= 10</measure>
    <time_frame>From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>The change from baseline in the proportion of patients with PHQ-9 &gt;= 10 is assessed at week 8 and 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Disability</measure>
    <time_frame>From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>It is measured by the Inflammatory Bowel Disease (IBD) Disability Index at weeks 8 and 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Overall quality of life</measure>
    <time_frame>From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>It is measured by the EuroQol 5-Dimensions, 5 Levels (EQ-5D-5L) and EQ5D VAS at weeks 8 and 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Ulcerative Colitis (UC)-specific quality of life</measure>
    <time_frame>From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>It is measured by the Short Quality of Life in Inflammatory Bowel Disease Questionnaire (SIBDQ) at weeks 8 and 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Fatigue</measure>
    <time_frame>From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>It is measured by the Functional Assessment Chronic Illness Therapy-Fatigue (FACIT-F) at weeks 8 and 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Sleep impairment,</measure>
    <time_frame>From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>It is measured by the Medical Outcomes Study Sleep scale (MOS Sleep) at weeks 8 and 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Work productivity</measure>
    <time_frame>From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>The change from baseline in work productivity is assessed at week 8 and 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing Simple Clinical Colitis Activity Index (SCCAI)</measure>
    <time_frame>Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>SCCAI is used to access response and remission rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Fecal Calprotectin levels</measure>
    <time_frame>From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>The change from baseline in Fecal Calprotectin levels will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mayo endoscopic sub-score</measure>
    <time_frame>Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>Mayo endoscopic sub-score will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Complications including hospitalization and surgery</measure>
    <time_frame>At Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>The proportion of patients with complications including hospitalization and surgery will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients on steroids</measure>
    <time_frame>At Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>The proportion of patients on steroids will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Physician's Global Assessment (PGA)</measure>
    <time_frame>From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation</time_frame>
    <description>The change from baseline in Physician's Global Assessment (PGA) will be assessed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Open-label cohort</arm_group_label>
    <description>Patients will be followed for 52 weeks post initiation of adalimumab (Week 0).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult males and females with moderate to severe UC patients from Canada who meet the
        inclusion criteria and who do not meet any of the exclusion criteria will be eligible for
        enrollment into the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must voluntarily sign and date a patient authorization.

          -  Patient must be ≥ 18 years of age.

          -  Patient must have confirmed diagnosis of UC.

          -  Patient must have:

               1. a Mayo endoscopic sub score of 2 or 3 from endoscopic investigation in the
                  previous 3-months that is closest to the baseline visit or

               2. a Mayo rectal bleeding subscore ≥ 2 and a calprotectin value greater than 250
                  µg/gr.

          -  Patient must have been prescribed adalimumab as part of his treatment by his treating
             physician.

          -  If the patient was previously treated with vedolizumab or any anti-TNF agent (except
             adalimumab), an appropriate washout has taken place as per routine practice.

        Exclusion Criteria:

          -  Patient has previously received adalimumab.

          -  Patient has previously used infliximab or any anti-TNF agent and have not clinically
             responded at any time (&quot;primary non-responder&quot;) unless they experienced a treatment
             limiting reaction.

          -  Patient with a history of subtotal colectomy with ileorectostomy or colectomy with
             ileoanal pouch, Kock pouch, or ileostomy for UC or planned bowel surgery.

          -  Patient with a current diagnosis of indeterminate colitis, ulcerative proctitis only,
             or with a current diagnosis and/or have a history of Crohn's disease.

          -  Patient with other tumor necrosis factor (TNF) immune-modulated disease.

          -  Patient has a significant history of renal, neurologic, psychiatric, endocrinologic,
             metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the
             investigator would adversely affect his/her participating in this study.

          -  A female patient is pregnant or breast-feeding.

          -  Patient is currently participating in another prospective study including controlled
             clinical trials and observational studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary /ID# 144032</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zeidler Ledcor Centre /ID# 145973</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Gastro Mgmnt Ltd /ID# 136820</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GIRI Gastrointestinal Research Institute /ID# 141107</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery Clinical Services /ID# 144102</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Percuro Clinical Research, Ltd /ID# 136533</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Everett Chalmers Reg Hosp. /ID# 136534</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 5N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Chadwick Ian Williams Professional Corporation /ID# 144802</name>
      <address>
        <city>St. John</city>
        <state>New Brunswick</state>
        <zip>E2K 1J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellini Medicine Professional /ID# 144241</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6S 0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oshawa Clinic /ID# 144364</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 1B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital /ID# 139392</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kensington Screening Clinic /ID# 141106</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M53 TA9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hosp.-Toronto /ID# 141108</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr O Tarabain Medicine Prof Corp /ID# 144034</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Rahman Bacchus Med. Corp. /ID# 141780</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8Y 4C9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel-Dieu de Levis /ID# 137099</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Maisonneuve-Rosemont /ID# 137336</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Saint-Luc /ID# 139393</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill Univ HC /ID# 136821</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique MEDI-CLE /ID# 153690</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3P 3E5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-Universite Laval /ID# 147557</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS - Hopital Fleurimont /ID# 137840</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Univ. Hosp, Saskatoon,CA /ID# 137838</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Real-life effect</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Patient reported outcomes (PRO)</keyword>
  <keyword>Moderate to severe ulcerative colitis (UC)</keyword>
  <keyword>Ulcerative colitis (UC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

